All In Biotech

Drug Trial Radar · NCT06274528

DORA and LP in Alzheimer's Disease Biomarkers

Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

201

Planned (sponsor's estimate)

Start

Mar 11, 2024

Primary completion

Mar 31, 2030

Study completion Mar 31, 2030

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); Eisai Inc.; National Institute on Aging (NIA)
First posted
Feb 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

  • Lemborexant 10 mgDrug

    Within FDA approved dose 10 mg; capsule; QD, 6 month duration

  • Lemborexant 20mgDrug

    20 mg; capsule; QD; 6 month duration

  • PlaceboDrug

    0 mg; capsule; QD; 6 month duration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes plasma pT181/T181 ratio of lemborexant 10 and 20 mg compared to PlaceboTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University in St. Louis, School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.